Subscribe

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology - FDA Approvals, Multiple Myeloma

On December 18, 2020, the FDA approved selinexor (Xpovio; Karyopharm Therapeutics) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adults with multiple myeloma after ≥1 previous therapies. The FDA granted this indication an orphan drug designation.

Selinexor was previously approved in combination with dexamethasone for adults with relapsed or refractory multiple myeloma who have received ≥4 previous therapies, and for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after ≥2 lines of systemic therapy.

The FDA approved the new indication based on data from the BOSTON clinical trial, a randomized, open-label, multicenter, active comparator–controlled study in patients with relapsed or refractory multiple myeloma who had received between 1 and 3 previous therapies. Patients were randomized in a 1:1 ratio to once-weekly selinexor orally, in combination with once-weekly bortezomib subcutaneously and low-dose dexamethasone twice-weekly (SVd) or to the standard twice-weekly bortezomib plus low-dose dexamethasone (Vd) regimen.

The main end point was progression-free survival (PFS). The estimated median PFS was 13.9 months (95% confidence interval [CI], 11.7-not estimable) in the SVd arm versus 9.5 months (95% CI, 7.6-10.8) in the Vd arm (estimated hazard ratio, 0.70; 95% CI, 0.53-0.93).

The most common (≥20%) adverse reactions reported with the SVd arm were nausea, fatigue, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting. Grade 3 or 4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia hyponatremia, and neutropenia.

Related Items
Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker
Web Exclusives published on June 16, 2021 in FDA Approvals
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
Web Exclusives published on June 16, 2021 in FDA Approvals
Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation
Web Exclusives published on June 16, 2021 in FDA Approvals
Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma
Web Exclusives published on June 16, 2021 in FDA Approvals
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
Web Exclusives published on May 17, 2021 in FDA Approvals
Last modified: July 6, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.